Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Abstract

Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432.).

Keywords

AvelumabUrothelial carcinomaMetastatic Urothelial CarcinomaChemotherapyOncologyMedicineInternal medicineCarcinomaStandard of careImmunotherapyCancerBladder cancerPembrolizumab

Affiliated Institutions

Related Publications

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Balaji Venugopal , Christian Kollmannsberger , Sylvie Négrier +25 more

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced ...

2019 New England Journal of Medicine 2439 citations

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen , Denis Soulières , Christophe Le Tourneau +97 more

There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageabl...

2018 The Lancet 1593 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares , Alexander Luft , David Vicente +20 more

In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in si...

2018 New England Journal of Medicine 3472 citations

Publication Info

Year: 2020
Type: article
Volume: 383
Issue: 13
Pages: 1218-1230
Citations: 1374
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1374

OpenAlex

Cite This

APA Style

                            
                                
                                    Thomas Powles, 
                                
                                    Se Hoon Park, 
                                
                                    Éric Voog
                                
                                et al.
                            
                            (2020). 
                            Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. 
                            New England Journal of Medicine
                            , 383
                            (13)
                            , 1218-1230.
                            https://doi.org/10.1056/nejmoa2002788
                        

Identifiers

DOI: 10.1056/nejmoa2002788